Key Takeaways:
- OpenEvidence, a telehealth startup, has raised $200 million twice, valuing the company at over $6 billion.
- The company’s valuation is expected to double to $12 billion in its next reported round.
- OpenEvidence’s success is part of a larger trend of AI-based startups in the healthcare industry, with companies like Abridge and Hippocratic AI also closing multiple mega-rounds.
- The use of AI in healthcare is becoming increasingly popular, with applications in drug discovery, back office operations, and patient care.
- The J.P. Morgan Healthcare Conference is a prominent event where healthcare companies and investors gather to discuss the future of the industry.
Introduction to OpenEvidence
OpenEvidence has become a well-known name among physicians, thanks to its chatbot that answers day-to-day clinical questions. As Katie Palmer, a reporter covering telehealth and clinical artificial intelligence, notes, the company’s success is not surprising, given its innovative approach to healthcare. With its valuation at over $6 billion, OpenEvidence is one of the most successful startups in the healthcare industry. As Palmer reports, "OpenEvidence has rapidly become a household name among physicians, with a chatbot that answers their day-to-day clinical questions." The company’s ability to provide accurate and timely information to physicians has made it an essential tool in the healthcare industry.
The Rise of AI in Healthcare
The success of OpenEvidence is part of a larger trend of AI-based startups in the healthcare industry. As Palmer notes, "Investors’ exuberance for OpenEvidence is emblematic of the AI froth that has taken over health care, and JPM, in the last two years — applying the technology, and in particular its generative variety, to everything from drug discovery to back office operations to patient care." This trend is expected to continue, with more companies using AI to improve healthcare outcomes and reduce costs. According to Rock Health’s 2025 digital health funding report, AI-based startups Abridge and Hippocratic AI, along with OpenEvidence, have all closed multiple mega-rounds this year. As the report notes, "AI-based startups have been particularly successful in raising funding, with many companies using the technology to improve healthcare outcomes and reduce costs."
The J.P. Morgan Healthcare Conference
The J.P. Morgan Healthcare Conference is one of the most prominent events in the healthcare industry, where companies and investors gather to discuss the future of healthcare. This year, OpenEvidence took its first step onto the stage, presenting its vision for the future of healthcare to investors. As Palmer reports, "It doesn’t come as much of a surprise, then, that the four-year-old startup took its first step onto the stage this year at the J.P. Morgan Healthcare Conference, where many of the health care industry’s most prominent players lay out their grand visions for investors." The conference provides a platform for companies like OpenEvidence to showcase their innovative solutions and attract investors.
The Future of Healthcare
The use of AI in healthcare is expected to continue to grow, with more companies using the technology to improve healthcare outcomes and reduce costs. As Palmer notes, "The use of AI in healthcare is becoming increasingly popular, with applications in drug discovery, back office operations, and patient care." The future of healthcare is likely to be shaped by AI, with companies like OpenEvidence leading the way. As the healthcare industry continues to evolve, it will be interesting to see how AI is used to improve healthcare outcomes and reduce costs. With its innovative approach to healthcare, OpenEvidence is well-positioned to play a major role in shaping the future of the industry.
Conclusion
In conclusion, OpenEvidence’s success is part of a larger trend of AI-based startups in the healthcare industry. The company’s innovative approach to healthcare, using a chatbot to answer day-to-day clinical questions, has made it an essential tool for physicians. The use of AI in healthcare is expected to continue to grow, with more companies using the technology to improve healthcare outcomes and reduce costs. As Palmer notes, "The future of healthcare is likely to be shaped by AI, with companies like OpenEvidence leading the way." With its valuation at over $6 billion, OpenEvidence is one of the most successful startups in the healthcare industry, and its success is likely to continue in the future.
At JPM, doctors’ darling OpenEvidence says it’s pursuing ‘medical super-intelligence’